Uterine fibroids are a painful condition that may also create serious limitations on a patient's reproductive options. This new text from an acknowledged expert at a major regional referral center fully reviews the relevant diagnostic factors as well as the potential new medical treatments and current thinking about the various - sometimes controversial - surgical options available for management.
Print versions of this book also include access to the eBook version with links to procedural videos.
| Contributors |
|
vii | |
|
1 The Health Care Costs of Uterine Fibroids |
|
|
1 | (3) |
|
|
|
|
|
2 Environmental Chemicals and Risk of Uterine Leiomyomata |
|
|
4 | (11) |
|
|
|
3 Dietary Factors and Uterine Fibroids |
|
|
15 | (7) |
|
|
|
|
|
|
|
|
|
22 | (5) |
|
|
|
5 Genetics of Uterine Leiomyomata |
|
|
27 | (9) |
|
|
|
|
|
6 Growth Patterns and Endometrial Changes |
|
|
36 | (4) |
|
|
|
|
|
40 | (3) |
|
|
|
|
|
|
|
|
|
|
|
43 | (7) |
|
|
|
|
|
9 Leiomyomata and Reproduction |
|
|
50 | (4) |
|
|
|
|
|
10 Hormonal Regulation in the Treatment of Fibroids |
|
|
54 | (7) |
|
|
|
|
|
11 The Role of Gonadotropin-Releasing Hormone (GnRH) Agonists in the Treatment of Uterine Fibroids |
|
|
61 | (3) |
|
|
|
|
|
12 GnRH Antagonists in the Treatment of Uterine Fibroids |
|
|
64 | (7) |
|
|
|
|
|
13 Role of Aromatase Inhibitors (AIs) and Selective Estrogen Receptor Modulators (SERMs) in the Treatment of Uterine Leiomyoma |
|
|
71 | (4) |
|
|
|
|
|
|
|
75 | (3) |
|
|
|
|
|
15 Alternative Therapies in the Treatment of Uterine Leiomyoma |
|
|
78 | (4) |
|
|
|
16 Laparotomy for Surgical Treatment of Uterine Fibroids |
|
|
82 | (6) |
|
|
|
|
|
17 Laparoscopic Myomectomy |
|
|
88 | (4) |
|
|
|
|
|
18 Computer-Assisted Laparoscopic Myomectomy |
|
|
92 | (7) |
|
|
|
|
|
19 Hysteroscopic Vaporization of Uterine Myoma |
|
|
99 | (4) |
|
|
|
|
|
20 Hysteroscopic Myomectomy |
|
|
103 | (5) |
|
|
|
|
|
21 Fibroids: Location is (Almost) Everything |
|
|
108 | (5) |
|
|
|
|
|
22 Manual or Hand Morcellation in Minimally Invasive Surgery |
|
|
113 | (4) |
|
|
|
|
|
|
|
23 Uterine Leiomyosarcoma |
|
|
117 | (5) |
|
|
|
|
|
|
|
122 | (4) |
|
|
|
|
|
|
|
126 | (5) |
|
|
|
|
|
26 How Long Does it Take Uterine Scar(s) to Heal? |
|
|
131 | (4) |
|
|
|
|
|
27 When to Recommend a Cesarean Section |
|
|
135 | (5) |
|
|
|
|
|
28 Uterine Artery Embolization |
|
|
140 | (5) |
|
|
|
Eric Paul Wehrenberg-Klee |
|
|
29 Magnetic Resonance-Guided Focused Ultrasound (MRgFUS) |
|
|
145 | (4) |
|
|
| Index |
|
149 | |
John C. Petrozza is a Reproductive Endocrinologist, Reproductive Surgeon, and Chief, Division of Reproductive Medicine. He is also IVF Director, Massachusetts General Fertility Center and Co-Director, MGH Integrated Fibroid Program, Boston and Danvers, Massachusetts, USA. He has focused on the surgical aspect of infertility and reproduction, including fibroids, endometriosis, surgical repair of uterine anomalies and scar tissue, and repair of damaged fallopian tubes. He also directs a Chronic Pelvic Pain Clinic within the gynecology division and co-directs the Minimally Invasive Gynecologic Surgery Program. He has a strong interest in fertility treatment outcomes and policies.
More info about Taylor & Francis e-books